After BioNTech’s acquisition of CureVac closes, BioNTech will pay GSK another $130 million and a 1% royalty on rest-of-world ...

This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...

BioNTech reaches agreement to get a non-exclusive license for mRNA-based Covid-19 and/or influenza products and resolve patent litigation with CureVac & GSK: Mainz, Germany Monday ...

GSK (NYSE:GSK) announced Monday that the U.S. Food and Drug Administration has accepted its priority review application for ...

Lack of mRNA funding could pose a national security risk; CureVac, GSK settle mRNA suit against Pfizer, BioNTech; Gilead confident in HIV prevention drug prospects.

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

CureVac ( (CVAC)) has provided an announcement. On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

Flutter Entertainment (FLTR) upped full-year guidance after a solid second quarter, with group revenue up 16 per cent to $4.2bn (£3.1bn) and adjusted Ebitda climbing 25 per cent to $919mn. Average ...

GSK provides update on US settlement of CureVac/BioNTech mRNA patent litigation: London, UK Saturday, August 9, 2025, 10:00 Hrs [IST] GSK plc announces that, in connection with th ...

This week in Other Barks & Bites: the USPTO terminates 52,000 trademark applications and registrations via sanctions; the ...

Stocks in the health-care industry rose as markets grew more confident that U.S. borrowing costs will fall, while companies in the sector pleased investors in their quarterly reports. Gilead Sciences ...